Strategic Partnerships Merus maintains an active collaboration ecosystem around its Biclonics bispecific antibodies, including exclusive licenses for Zeno with Partner Therapeutics and a diagnostic collaboration with Foundation Medicine. This setup creates ready pathways to expand partnerships with pharma, biotechs, and diagnostics for co-development, licensing, and commercialization.

Delivery Innovation Subcutaneous formulation development with Halozyme demonstrates a move toward patient-friendly delivery and potentially more flexible dosing. This opens conversations with contract manufacturers, payers, and regional partners about rapid market access and differentiated value propositions.

High-Value Assets High-value assets such as Zenocutuzumab and related programs reflect a strong asset footprint that may attract late-stage collaboration or acquisition discussions in the market. This context offers opportunities for strategic alliances, co-development, and staged licensing with global partners.

Targeted Patient Access Focus on NRG1+ non-small cell lung cancer and pancreatic cancer, paired with companion diagnostics via Foundation Medicine, enables targeted patient selection. BD opportunities exist to partner with diagnostic firms and CROs to accelerate patient enrollment and payer alignment for precision therapy.

Global Readiness Global footprint, sustained funding, and a public-market presence enhance Merus' ability to execute cross-border licensing, co-commercialization, and international clinical collaborations. This positions the company to engage multinational partners and accelerate deal progress through a well-resourced platform.